Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Laser Photonics Reports Full Year Total Net Sales Increase of 144% in Q4 2025 Financial Results (click to learn more) This Bitcoin-focused microcap is building a treasury strategy centered on accumulating BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News ImageneBio Inc IMA

Healthcare Biotechnology
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IMA)

ImageneBio Announces $30 Million Private Placement

GlobeNewswire 8 days ago

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 17, 2026

ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

GlobeNewswire March 10, 2026

ImageneBio to Participate in Leerink Global Healthcare Conference

GlobeNewswire February 26, 2026

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

GlobeNewswire February 10, 2026

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

GlobeNewswire November 12, 2025

ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

GlobeNewswire November 6, 2025

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 1, 2025

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

GlobeNewswire July 25, 2025
View More News ››

Opinion & Analysis (NDAQ:IMA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IMA)

Be the first to post on this bullboard.

Specificity Inc.

Specificity Inc.

Specificity, Inc. operates as a digital marketing company in the United States and internationally. It offers Tradigital ...
View More »

Podcasts